NCT02307396

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Technical University of Munich · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the medication seems appropriate. Relapse is defined as primary outcome.

Detailed description

The main objective of the trial is to evaluate for the first time, how long an antipsychotic relapse-prevention should be continued and to which time a patient is protected enough, so that a guided withdrawal or reduction of the medication seems appropriate. Relapse is defined as primary outcome. We include patients with schizophrenia or schizoaffective disorder in remission for at least 3 years under a stable antipsychotic medication.

Conditions

• Schizophrenia
• Schizophrenia and Disorders With Psychotic Features
• Schizoaffective Disorders

Interventions

Type	Name	Description
DRUG	Olanzapine
DRUG	Amisulpride
DRUG	Risperidone
DRUG	Haloperidol
DRUG	Quetiapine
DRUG	Perphenazine
DRUG	Sulpiride
DRUG	bromperidol
DRUG	Zuclopenthixol
DRUG	Thioridazine
DRUG	Paliperidone
DRUG	Ziprasidone
DRUG	Benperidol
DRUG	Fluspirilene
DRUG	Pimozide
DRUG	Perazine
DRUG	Fluphenazine
DRUG	Flupentixole
DRUG	Sertindole

Timeline

• Start date: 2015-02-01
• Primary completion: 2016-06-22
• Completion: 2016-06-22
• First posted: 2014-12-04
• Last updated: 2018-10-11

Locations

1 site across 1 country: Germany